John Mandrola, MD, FACC
April 5th, 2012
When the Feds Come Knocking
Westby G Fisher, MD and John Mandrola, MD, FACC
CardioExchange welcomes this guest post from electrophysiologists Westby Fisher and John Mandrola. This piece originally appeared on their respective blogs, Dr. Wes and Dr. John M. Slightly over a year ago, the Department of Justice (DOJ) launched an investigation of a large number of institutions regarding concerns that implantable cardiac defibrillator (ICD) procedures were performed for […]
July 14th, 2011
Rivaroxaban: The Next Non-Warfarin Oral Blood Thinner
John Mandrola, MD, FACC
An electrophysiologist and blogger places the recent approval of rivaroxaban in the context of the seismic changes that have taken place and that are still expected in the anticoagulant marketplace.
July 1st, 2011
AF Update: Flecainide Misinformation
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. I have said that the best tool for treating atrial fibrillation (AF) is education. I still strongly believe that, perhaps more than ever. AF presents itself to people in so many different ways – from […]
May 9th, 2011
Words, ICDs, and Patient-Centered Medicine…
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. Guess what made the heart rhythm newswire yesterday? It wasn’t a new medicine, or a new stent, not even a new ablation catheter, and it surely wasn’t a revolution in motivating people to exercise. It was words. […]
March 25th, 2011
The Best Tool for Treating Atrial Fibrillation
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. Today, I would like to tell you about the most effective way to treat the most common heart ailment — atrial fibrillation (AF). It’s not the novel new blood-thinner, dabigatran (Pradaxa). Though it’s […]
December 23rd, 2010
John Mandrola: Looking Back at 2010 and Ahead to 2011
John Mandrola, MD, FACC
To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. By far, the number one heart story of 2010 was the release of the novel blood-thinning drug, dabigatran (Pradaxa), for the prevention of stroke […]
November 5th, 2010
Independent doctors?
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. In response to my story on how physician consolidation and hospital ownership of doctors is affecting patient referral patterns, I received an email with this attached PDF file. (Smudges mine) It is from […]
October 20th, 2010
Dabigatran Is Approved
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. There can only be one cardiology story to discuss today. Tuesday, the FDA approved dabigatran (Pradaxa), an oral anticoagulant for the prevention of stroke in atrial fibrillation. Previously, the only drug approved to prevent stroke in […]
September 30th, 2010
Don’t Take My Fun Away
John Mandrola, MD, FACC
John Mandrorla is a cardiac electrophysiologist and blogger on matters medical and general. In a recent post to his blog Dr John M, he celebrates his enduring sense that doctoring is still a great job.
September 21st, 2010
See Everything
John Mandrola, MD, FACC
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. Do you see anything wrong with this picture? (Hint: see the right column) I guess the European electrophysiologists couldn’t wait for us in North America. They have published their own 54,000 word Euro-specific guidance […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?